In another in vitro study on glioblastoma by Morimoto and colleagues, the knockout of TIM-3 with the use of CRISPR/Cas9 technology was shown to be beneficial in increasing inhibition of glioblastoma tumor cell growth without interfering with the expression of other NK cell inhibitory receptors [142]. This evidence concerns the gene HAVCR2 and neoplasm.